Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia

Transfusion

Volumn 53, Issue 2, 2013, Pages 261-269

  Tremblay, Tony ^b   Paré, Isabelle ^b   Bazin, Renée ^a  

^a Héma Québec ^*  (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PLASMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOPRECIPITATION; MOUSE; NONHUMAN;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; BLOOD PROTEINS; DIMERIZATION; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MICE, INBRED BALB C; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME;

EID: 84873435597     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03725.x     Document Type: Article

References (39)

1. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP,. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-31.
2. Fehr J, Hofmann V, Kappeler U,. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306: 1254-8.
3. Salama A, Mueller-Eckhardt C, Kiefel V,. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983; 2: 193-5.
4. Song S, Crow AR, Freedman J, Lazarus AH,. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 2003; 101: 3708-13.
5. Crow AR, Song S, Freedman J, Helgason CD, Humphries RK, Siminovitch KA, Lazarus AH,. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 2003; 102: 558-60.
6. Samuelsson A, Towers TL, Ravetch JV,. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-6.
7. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV,. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475: 110-3.
8. Guhr T, Bloem J, Derksen NI, Wuhrer M, Koenderman AH, Aalberse RC, Rispens T,. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS ONE 2011; 6: e21246.
9. Leontyev D, Katsman Y, Ma XZ, Miescher S, Kasermann F, Branch DR,. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 2012; 52: 1799-805.
10. Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH,. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006; 12: 688-92.
11. Yu Z, Lennon VA,. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227-8.
12. Crow AR, Suppa SJ, Chen X, Mott PJ, Lazarus AH,. The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia. Blood 2011; 118: 6403-6.
13. Augener W, Friedmann B, Brittinger G,. Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)? Blut 1985; 50: 249-52.
14. Smith NA, Chakraverty RK, Boughton BJ,. The successful treatment of idiopathic thrombocytopenic purpura with the low dose non specific IgG component of anti D immunoglobulin. Clin Lab Haematol 1990; 12: 131-6.
15. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE, Bleeker WK,. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98: 1095-9.
16. Clynes R,. Immune complexes as therapy for autoimmunity. J Clin Invest 2005; 115: 25-7.
17. Lamoureux J, Aubin E, Lemieux R,. Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: a role in the in vivo mechanisms of action of IVIg? Int Immunol 2004; 16: 929-36.
18. Lemieux R, Bazin R,. Autoantibody-induced formation of immune complexes in normal human serum. Curr Pharm Des 2006; 12: 173-9.
19. Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH,. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 2005; 115: 155-60.
20. Ravetch JV,. Fc receptors: rubor redux. Cell 1994; 78: 553-60.
21. St-Amour I, Laroche A, Bazin R, Lemieux R,. Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins. Clin Immunol 2009; 133: 52-60.
22. Bazin R, Lemieux R, Tremblay TS, Amour I,. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br J Haematol 2004; 127: 90-6.
23. Tremblay T, Aubin E, Lemieux R, Bazin R,. Picogram doses of lipopolysaccharide exacerbate antibody-mediated thrombocytopenia and reduce the therapeutic efficacy of intravenous immunoglobulin in mice. Br J Haematol 2007; 139: 297-302.
24. Ballow M,. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38: 122-32.
25. Gupta RC, McDuffie FC, Tappeiner G, Jordon RE,. Binding of soluble immune complexes to Raji lymphocytes. Role of receptors for complement components, C1q and C3-C3b. Immunology 1978; 34: 751-61.
26. Lightfoote M, Folks TM, Redfield R, Gold J, Marti GE, Kelly J, Sell KW,. Flow-cytometric detection of circulating immune complexes. J Immunol Methods 1986; 95: 107-12.
27. Lazarus AH, Crow AR,. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003; 28: 249-55.
28. Nimmerjahn F, Ravetch JV,. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513-33.
29. Bazin R, Lemieux R, Tremblay T,. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol 2006; 135: 97-100.
30. Deng R, Balthasar JP,. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. Blood 2007; 109: 2470-6.
31. Huang HS, Sun DS, Lien TS, Chang HH,. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice. Blood 2010; 116: 5002-9.
32. Katsman Y, Foo AH, Leontyev D, Branch DR,. Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction. Transfusion 2010; 50: 1285-94.
33. Song S, Crow AR, Siragam V, Freedman J, Lazarus AH,. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 2005; 105: 1546-8.
34. van Mirre E, Teeling JL, van der Meer JW, Bleeker WK, Hack CE,. Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcgammaRII and FcgammaRIIIb. J Immunol 2004; 173: 332-9.
35. Clynes R,. Protective mechanisms of IVIG. Curr Opin Immunol 2007; 19: 646-51.
36. Salama A, Kiefel V, Amberg R, Mueller-Eckhardt C,. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D). Blut 1984; 49: 29-35.
37. Cooper N, Heddle NM, Haas M, Reid ME, Lesser ML, Fleit HB, Woloski BM, Bussel JB,. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol 2004; 124: 511-8.
38. Knezevic-Maramica I, Kruskall MS,. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43: 1460-80.
39. Teeling JL, De Groot ER, Eerenberg AJ, Bleeker WK, Van Mierlo G, Aarden LA, Hack CE,. Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro. Clin Exp Immunol 1998; 114: 264-70.